Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.52 |
| ▸ | DRD1 | P21728 | 7/20 | 0.52 |
| ▸ | DRD4 | P21917 | 7/20 | 0.52 |
| ▸ | DRD5 | P21918 | 7/20 | 0.52 |
| ▸ | DRD3 | P35462 | 7/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531102 | 0.85 | SIGMAR1 (0.42) | DRD2DRD4DRD3SIGMAR1MEN1 | |
| SCHEMBL12320891 | 0.82 | SLC18A3 (0.67) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL7480157 | 0.82 | DRD2 (0.74) | DRD2HTR2C | |
| SCHEMBL6198442 | 0.82 | SIGMAR1 (0.69) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL11280755 | 0.79 | HTR7 (0.53) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL11619057 | 0.78 | HTR2C (0.61) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4083042 | 0.77 | DRD2 (0.49) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4083055 | 0.77 | DRD2 (0.68) | DRD2MCHR1 | |
| SCHEMBL5729329 | 0.77 | SIGMAR1 (0.69) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL28755949 | 0.77 | SIGMAR1 (0.48) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444675-B2 | PROMOTING WEIGHT LOSS AND TREATING EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-03 | — | — | US | disclosed |
| US-20010049370-A1 | 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists | SIT SING-YUEN (US) | 2001-12-06 | — | — | US | disclosed |
| WO-2001085690-A1 | 4-ALKYL AND 4-CYCLOALKYL DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049370-A1 | 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists | NPY4R, NPY1R, NPY5R | DRD2 164/4885DRD1 188/4885DRD4 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.